The Global Schizophrenia Drugs Market is projected to grow significantly, with an expected market size of USD 12.6 billion by 2032, up from USD 7.4 billion in 2022, at a compound annual growth rate ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

Alkermes plc last week announced it had completed the sale of its development and manufacturing facility in Athlone, to Novo ...

The global Opioid Use Disorder (OUD) market has witnessed significant growth in recent years, driven by various factors ...

Damon Warnock, who has a wealth of knowledge and experience having worked for global biopharmaceutical company Alkermes and previously with Irish firm Elan, has been appointed to the role at the ...

Throughout the last three months, 7 analysts have evaluated Alkermes (NASDAQ:ALKS), offering a diverse set of opinions from ...

The class 2 Elm in Coláiste Chiaráin were chosen to take part in this year’s World of Work Programme which is run in ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which ...

Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which missed the Zacks Consensus Estimate of 59 cents. The company had ...

ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first ...